<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1    INDICATIONS AND USAGE <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:<BR>                        <BR>                           Head and Neck Cancer<BR>                        <BR>                        <BR>                           Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. (1.1, 14.1)<BR>                           <BR>                           Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU.  (1.1, 14.1)<BR>                           <BR>                           Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. (1.1, 14.1)<BR>                           <BR>                        <BR>                        <BR>                           Colorectal Cancer<BR>                        <BR>                        <BR>                           K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved tests<BR>                        <BR>                           in combination with FOLFIRI for first-line treatment,<BR>                           <BR>                           in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,<BR>                           <BR>                           as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. (1.2, 5.7, 12.1, 14.2)<BR>                           <BR>                        <BR>                        <BR>                          Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation-positive colorectal cancer. (5.7, 14.2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1   Squamous Cell Carcinoma of the Head and Neck (SCCHN)<BR>                     <BR>                        Erbitux® is indicated in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. [See Clinical Studies (14.1)<BR>                           .]<BR>                        Erbitux is indicated in combination with platinum-based therapy with 5-FU for the first-line treatment of patients with recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck. [See Clinical Studies (14.1)<BR>                           .]<BR>                        Erbitux, as a single agent, is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed. [See Clinical Studies (14.1)<BR>                           .]<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2   K-Ras Mutation-negative, EGFR-expressing Colorectal Cancer<BR>                     <BR>                        <BR>                           Erbitux is indicated for the treatment of K-Ras mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use [see Dosage and Administration (2.2)<BR>                              , Warnings and Precautions (5.7)<BR>                              , Clinical Studies (14.2)<BR>                              ]<BR>                        <BR>                        <BR>                           <BR>                              in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for the first-line treatment,<BR>                           <BR>                           <BR>                              in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,<BR>                           <BR>                           <BR>                              as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. [See Warnings and Precautions (5.7)<BR>                                 , Clinical Pharmacology (12.1)<BR>                                 , Clinical Studies (14.2)<BR>                                 .]<BR>                           <BR>                        <BR>                        <BR>                            Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation-positive colorectal cancer [see Warnings and Precautions (5.7)<BR>                              , Clinical Studies (14.2)<BR>                              ].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>